Ncardia

24/12/2022

Ho ho ho, the Ncardia team getting into the Christmas spirit! Happy holidays from the team and Santa! 🎅🎄

03/02/2022

Final webinar of our series dedicated to neurodegenerative diseases! Sign up and learn how human iPSCs can be utilized to model disease-relevant signatures of Alzheimer's disease. In this 15-min webinar, our senior neuroscientist, Laura Calo, will present a model of tauopathy in hiPSC-derived cortical neurons and how to use it for drug discovery purposes.

Thursday February 17th | 3PM CET - 9AM ET

Sign up now and secure your spot!
http://ow.ly/epTv50HGkQM

02/02/2022

Learn more about human iPSC technology and how it can benefit your drug discovery projects. Subscribe to our newsletter and keep up-to-date with our latest innovations, news and events.
Every 2 months you will receive information on the most relevant advancements and applications of human iPSCs in early drug discovery.

Subscribe now http://ow.ly/ixbB50HGjAv

01/02/2022

Obtain robust and predictive conclusions about the safety and efficacy of your compounds with our integrated drug discovery solutions based on human iPSC technology.

✔️Custom solutions
✔️Flexible and accessible team
✔️Efficient ex*****on
✔️Processed results

> Explore http://ow.ly/Eeyx50HGgoL

27/01/2022

Leveraging patient-specific background data in your preclinical research, using iPSC technology, will enable you to advance your cardiac drug discovery project more efficiently. Discover this and more advantages of using iPSC-based cardiac models in your drug discovery projects.

Learn more: http://ow.ly/xBwI50HBqCc

26/01/2022

Assess electrophysiology, contractility and cardiac Troponin I release of human iPSC-cardiomyocytes with our multiparametric functional and structural cardiac safety analysis.

- Acute and long term analysis
- Reproducible results
- Clinically relevant

Learn more http://ow.ly/EuMq50HzB1b

25/01/2022

We had a fantastic webinar session last week! Thanks to all the attendees for coming and promoting interesting discussions with our scientists Calo and Onofre.
In case you missed it, here is the replay

In this webinar, learn about the benefits and challenges of hiPSC-derived neuronal and glial cells and optimized assays to model neurodegeneration

20/01/2022

Last spots available! Gain insights into how human iPSC-derived neuronal and glial cells can model especific phenotypes associated with neurodegeneration.

Sign up now👉http://ow.ly/Tac750HvPMH

19/01/2022

Obtain translational results of the safety and efficacy of cardioactive compounds using human iPSC-derived cardiomyocytes and our contractility analysis solutions.

This is a physiologically relevant assay available for iPSC-based cardiac in vitro models that mimics tissue elasticity in multi-well format and provides you with reproducible information.

Learn more 👉http://ow.ly/T6qx50HvOYZ

18/01/2022

Learn the benefits that human iPSC-derived cardiomyocytes bring to cardiac disease modeling and drug discovery. In this article, Kosmidis, senior scientist at Ncardia, discusses the key issues hampering the development of new therapies for cardiac diseases and explains the need to incorporate more physiologically relevant disease models in drug discovery.

👉http://ow.ly/2hqn50HvKbi

13/01/2022

Learn how to develop and optimize robust assays with human iPSC-derived neuronal cell types to recapitulate disease-specific phenotypes.
Join us for the live session with Q&A next Thursday 20th at 3PM

https://event.webinarjam.com/register/15/8q4r3av

12/01/2022

Developing and performing predictive assays to recapitulate disease phenotypes in high-throughput can be challenging. Explore our assay development solutions to find out how Ncardia can make this process easier for you.

✔️+ 10 years of experience with hiPSCs
✔️Clinically relevant readouts
✔️Miniaturized assays for high-throughput screenings

http://ow.ly/gWTw50Hpnwf